Neukine 300mcg injection

Every medicine has some side effects that typically manage on their own as your body gets used to the medicine, but some people may experience severe side effects rarely. In that case, the patient should contact the doctor immediately.

Some common side effects of Neukine 300mcg injection include:

• Bone pain
  
• Weakness
  
• Headache
  
• Rash
  
• Nausea
  
• Increased lactate dehydrogenase level in blood
  
• Vomiting
  
• Increased uric acid level in blood
  
• Oropharyngeal pain
  
• Hair loss
  
• Fatigue
  
• Diarrhea
  
• Constipation
  
• Decreased appetite
  
• Cough
  
• Breathing problems
  
• Injection site reactions (pain, swelling, redness)

Contact your healthcare provider if you face any unusual or persistent side effects.

Neukine 300mcg injection is a prescription-based drug. It is advised to take this injection after consulting your healthcare expert. This medicine should be given by an experienced nurse or doctor. Please do not self-administer.

Neukine 300mcg injection contains Filgrastim (300mcg) as an active ingredient. It works as a growth factor that stimulates the bone marrow (the tissue where new blood cells are formed) to produce more white blood cells (WBC) that help body to fight infection. It this way it prevents the infection after chemotherapy.

• Minallah, S., Farooqi, A. R., Shakeel, Z., Khan, A., Iqbal, H., & Sajjad, K. (2025). Impact of Filgrastim Versus Pegfilgrastim on Hospital Stay and Mortality Among Chemotherapy-Induced Febrile Neutropenia Patients. Journal of Health, Wellness and Community Research, e191-e191.
  
• Dale, D. C., Crawford, J., Klippel, Z., Reiner, M., Osslund, T., Fan, E., ... & Lyman, G. H. (2018). A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Supportive Care in Cancer, 26(1), 7-20.
  
• Rattu, M. A. (2023). Prevention and treatment of chemotherapy-induced febrile neutropenia in adults. US Pharm, 48(6), 25-30.
  
• Weycker, D., Barron, R., Edelsberg, J., Kartashov, A., Legg, J., & Glass, A. G. (2014). Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis. BMC health services research, 14(1), 189.
  
• Kuritzkes, D. R., Parenti, D., Ward, D. J., Rachlis, A., Wong, R. J., Mallon, K. P., ... & G-CSF 930101 Study Group. (1998). Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. Aids, 12(1), 65-74.
  
• Maher, D. W., Lieschke, G. J., Green, M., Bishop, J., Stuart-Harris, R., Wolf, M., ... & Morstyn, G. (1994). Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo-controlled trial. Annals of Internal medicine, 121(7), 492-501.